Dealing with hERG liabilities early: diverse approaches to an important goal in drug development.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Chemical and Structural Strategies to Selectively Target mTOR Kinase.ChemMedChem · 2021
   Review
2. A structure-based computational workflow to predict liability and binding modes of small molecules to hERG.Scientific reports · 2020
   Article
3. Druggability of Coronary Artery Disease Risk Loci.Circulation. Genomic and precision medicine · 2018
   Article
4. Phenylethynyl-substituted Heterocycles Inhibit Cyclin D1 and Induce the Expression of Cyclin-dependent Kinase Inhibitor p21MedChemComm · 2018
   Article
5. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.European journal of pharmacology · 2017
   Article
6. Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.Bioorganic & medicinal chemistry · 2017
   Article
7. Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.Bioorganic & medicinal chemistry letters · 2016
   Article
8. From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter.MedChemComm · 2016
   Article
9. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.Organic & biomolecular chemistry · 2016
   Article
10. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.British journal of pharmacology · 2012
    Article
11. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.British journal of pharmacology · 2010
    Review

Corrections and comments

• Comment on
  An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.2010

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as